Women's Opioid Treatment Follow-up Study
Key facts
- Who runs it
- Mclean Hospital
- Where
- Belmont, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 39 people enrolled
- Started
- 8 Mar 2024
- Ended
- 16 Oct 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Gender-specific digital intervention (GSDI)
- Treatment as usual
- Record updated
- 13 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- age 18 years of age or older
- current opioid use disorder diagnosis
- have a smartphone
- initiated medication treatment for opioid use disorder in the past 30 days,
- able to provide informed consent
Who cannot take part
- an acute psychiatric or medical condition, or cognitive impairment, that would impair the ability to complete study procedures
- admitted to their current treatment episode on an involuntary status
Where in United States
- McLean HospitalBelmont, United States
About the trial
What the trial wants to find out
The goal of this study is to examine the feasibility of a gender-specific digital intervention for women with opioid use disorder. In this study, women with opioid use disorder will be randomized to receive treatment-as-usual plus a gender-specific digital intervention or treatment-as-usual only. Feasibility, satisfaction, and engagement with the intervention are the primary outcomes and will be measured post-intervention and at two-week, 6-week, and 12-week follow-up visits.
The 2 groups in the trial
- Gender-specific digital intervention plus treatment as usual (GSDI+TAU)Treatment being tested
GSDI + TAU includes the addition of a gender-specific digital intervention (GSDI) to treatment as usual. The GSDI has a web-based component and a mobile component. The web-based portion of the GSDI includes: (1) gender-specific psychoeducation on substance use disorders, (2) specific education on opioid use disorder, including information about medication treatment for opioid use disorder, and (3) information on relapse-prevention skills. Participants complete the web-based portion immediately after completing baseline assessments. The mobile component includes three parts: (1) weekly self-report surveys of opioid and other substance use and medication adherence, (2) weekly skills-practice exercises, and (3) daily motivational messages encouraging self-care. Participants engage with the mobile component after completing the web-based portion until the end of the study (12 weeks).
Treatment: Gender-specific digital intervention (GSDI) and Treatment as usual
- Treatment as usual (TAU)Other group
TAU for opioid use disorder consists of a mix of medication treatment and individual and group therapy services across various levels of care: inpatient, residential, and outpatient. Residential treatment is for adults who have completed detoxification and require additional treatment in a structured environment. Inpatient treatment includes short-term care and detoxification treatment and incorporates a combination of group, family, and individual therapy targeted at medical stabilization, reducing the severity of the patient's symptoms, and providing resources and ongoing support to prevent relapse. Outpatient treatment is focused on comprehensive evaluation and stabilization.
Treatment: Treatment as usual
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Increasing Women's Engagement in Medication Treatment for Opioid Use Disorder Through Digital Intervention
- Record updated
- 13 April 2026